A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab.

CONCLUSIONS: ACT of fresh NY-ESO-1 transgenic T cells prepared via a short ex vivo protocol and given with DC vaccination, with or without ipilimumab, is feasible and results in transient antitumor activity, with no apparent clinical benefit of the addition of ipilimumab. Improvements are needed to maintain tumor responses.
PMID: 30573690 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 20, 2018 Category: Cancer & Oncology Authors: Nowicki TS, Berent-Maoz B, Cheung-Lau GC, Huang RR, Wang X, Tsoi J, Kaplan-Lefko PJ, Cabrera P, Tran J, Pang J, Macabali MH, Perez Garcilazo I, Baselga Carretero I, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh AS, Tags: Clin Cancer Res Source Type: research